{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% confidence interval (CI) was not estimated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% confidence interval (CI) was not estimated due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% confidence interval (CI) was not estimated due to insufficient number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"234"}],"units":"Participants"}],"description":"The SALT uses a visual aid showing the division of the scalp hair into 4 areas with the top of the head constituting 40% of total surface, the posterior/back of head 24%, right side and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score, as developed by the National Alopecia Areata Foundation Working Committee. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account in the SALT scoring process. The SALT score will range from 0% to 100%, with lower score indicating better health outcomes. Kaplan-Meier method was used for analysis. Time for participants to achieve salt ≤ 20 at week 36 were reported in this outcome measure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Time for Participants to Achieve SALT ≤ 20 at Week 36.","type":"SECONDARY","unitOfMeasure":"Days"}